This increases the efficacy of antigen-specific presentation (MHC Class I) on naïve CD8+ T cells, leading to increased activation and proliferation of CD8+ T cells, allowing for better tumor surveillance [93]. The gene discussed is CD8A; the disease is neoplasm.